CapsoVision (NASDAQ:CV) Price Target Lowered to $10.00 at Benchmark

CapsoVision (NASDAQ:CV) had its price target dropped by analysts at Benchmark from $14.00 to $10.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a “speculative buy” rating on the stock. Benchmark’s target price would indicate a potential upside of 39.18% from the stock’s previous close.

Other equities analysts have also issued research reports about the stock. Wall Street Zen raised shares of CapsoVision to a “hold” rating in a research report on Saturday, January 10th. Weiss Ratings restated a “sell (e)” rating on shares of CapsoVision in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $8.50.

CapsoVision Trading Down 4.6%

CV stock traded down $0.35 during mid-day trading on Friday, hitting $7.19. The stock had a trading volume of 130,879 shares, compared to its average volume of 443,764. CapsoVision has a 1-year low of $3.43 and a 1-year high of $15.37. The company has a fifty day moving average of $5.55 and a 200 day moving average of $6.22. The stock has a market capitalization of $336.57 million and a price-to-earnings ratio of -3.28.

CapsoVision (NASDAQ:CV) last announced its quarterly earnings results on Thursday, March 26th. The company reported $0.02 earnings per share (EPS) for the quarter. The firm had revenue of $3.92 million for the quarter.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. New York State Common Retirement Fund acquired a new stake in CapsoVision in the 3rd quarter worth approximately $34,000. Deutsche Bank AG acquired a new position in CapsoVision during the fourth quarter valued at approximately $47,000. Wells Fargo & Company MN raised its position in shares of CapsoVision by 66.4% in the fourth quarter. Wells Fargo & Company MN now owns 6,287 shares of the company’s stock valued at $67,000 after purchasing an additional 2,508 shares during the period. Citadel Advisors LLC acquired a new stake in shares of CapsoVision in the third quarter worth $115,000. Finally, Virtu Financial LLC acquired a new stake in shares of CapsoVision in the fourth quarter worth $128,000.

About CapsoVision

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.